APPLICATION OF “EXACTO” SCALE TO ASSESS ANNUAL RESPONSE TO MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA.

<bold>Introduction:</bold> EXACTO (Exacerbations, ACT, systemic corticosteroids and Obstruction-FEV1) is a multidimensional scale that assesses response to biologic treatments, with two scores ranging from 0 to 10 or 0 to 7 depending on whether the patient is receiving continuous systemic glucocorticoids (CGC) or not. The aim of this study is to evaluate one-year response of patients on biologic therapy using the EXACTO scale. <bold>Methodoloy</bold> Retrospective descriptive study which analise demographic data, asthma history, comorbidities, exacerbations, maintenance corticosteroids, asthma control questionnaire (ACT), spirometry and eosinophilia at baseline and 12 months after treatment with Dupilumab, Benralizumab, Mepolizumab or Omalizumab. Quantitative variables are expressed as means and qualitative as percentages. <bold>Results:</bold> Baseline characteristics are shown in table 1 and comparison between baseline and one-year values in table 2. After applying the EXACTO scale to patients not on OCS, 4.35% of them had no response, 36.96% partial response, 50% good response and 8.69% a complete response (named super responders). Patients on OCS, 90.91% had partial response and 9.09% a complete response. <bold>Conclusion:</bold> 1. The majority of our patients are non-smoking women with eosinophilic T2 asthma. 2. After one year of biologic treatment exacerbations were reduced by more than half, ACT showed significant improvement, as also did lung function. 3. On an EXACT basis after one year of follow up, 49.12% of patients had at least a good response to treatment and 8.77% were super-responders.